JP2004532854A - 複素２環式ｆｋｂｐリガンド - Google Patents

複素２環式ｆｋｂｐリガンド Download PDF

Info

Publication number
JP2004532854A
JP2004532854A JP2002586941A JP2002586941A JP2004532854A JP 2004532854 A JP2004532854 A JP 2004532854A JP 2002586941 A JP2002586941 A JP 2002586941A JP 2002586941 A JP2002586941 A JP 2002586941A JP 2004532854 A JP2004532854 A JP 2004532854A
Authority
JP
Japan
Prior art keywords
compound
mmol
pharmaceutically acceptable
found
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2002586941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004532854A5 (https=
Inventor
チュアンシン・グウォウ
コリーン・イー・オージェリ−ソフラン
ナンシー・スー・バーター
スティーヴン・リー・ベンダー
クリストファー・フランクリン・ビッグ
ブラッドリー・ウィリアム・カプラーテ
アリンダム・チャッタージェー
ジューディス・ディール
リーミン・ドン
ロレイン・カスリーン・フェイ
シンジュン・ホウ
レイモンド・アンドルー・ハダック・ジュニア
ワーナー−ランバート・カンパニー
Original Assignee
アグロン ファ−マシュ−テイカルズ インコ−ポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アグロン ファ−マシュ−テイカルズ インコ−ポレイテッド filed Critical アグロン ファ−マシュ−テイカルズ インコ−ポレイテッド
Publication of JP2004532854A publication Critical patent/JP2004532854A/ja
Publication of JP2004532854A5 publication Critical patent/JP2004532854A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2002586941A 2001-05-10 2002-05-10 複素２環式ｆｋｂｐリガンド Abandoned JP2004532854A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28982801P 2001-05-10 2001-05-10
PCT/US2002/014966 WO2002089806A1 (en) 2001-05-10 2002-05-10 Heterobicycles fkbp-ligands

Publications (2)

Publication Number Publication Date
JP2004532854A true JP2004532854A (ja) 2004-10-28
JP2004532854A5 JP2004532854A5 (https=) 2005-12-22

Family

ID=23113278

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002586941A Abandoned JP2004532854A (ja) 2001-05-10 2002-05-10 複素２環式ｆｋｂｐリガンド

Country Status (6)

Country Link
EP (1) EP1423119A4 (https=)
JP (1) JP2004532854A (https=)
BR (1) BR0210060A (https=)
CA (1) CA2446795A1 (https=)
MX (1) MXPA03010255A (https=)
WO (1) WO2002089806A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009506988A (ja) * 2005-08-19 2009-02-19 エラン ファーマシューティカルズ，インコーポレイテッド ガンマセクレターゼの架橋ｎ−環状スルホンアミド阻害剤
JP2017523990A (ja) * 2014-08-27 2017-08-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｎｓ障害を処置するための置換ピラジノ［２，１−ａ］イソキノリン誘導体

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2690102A1 (en) 2012-07-24 2014-01-29 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bicyclic aza-amides for treatment of psychiatric disorders
EP2899192A1 (en) * 2014-01-24 2015-07-29 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diazabicyclo[4.3.1]decane derivatives for treatment of psychiatric disorders
WO2015110271A1 (en) * 2014-01-24 2015-07-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Diazabicyclo[4.3.1]decane derivatives for treatment of psychiatric disorders
US10597378B2 (en) 2017-09-08 2020-03-24 National Health Research Institutes Tetrahydroisoquinolines for use as MOR/NOP dual agonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3880927A (en) * 1972-06-19 1975-04-29 Lilly Co Eli {62 -Phenyl-{62 ,{62 -difluoroethylamines
PT1098897E (pt) * 1998-07-17 2004-10-29 Agouron Pharma Compostos composicoes e metodos para estimular o crescimento e a elongacao neuronal
US6818643B1 (en) * 1999-12-08 2004-11-16 Bristol-Myers Squibb Company Neurotrophic bicyclic diamides
AU2001292160A1 (en) * 2000-10-19 2002-04-29 Pfizer Products Inc. Bridged piperazine derivatives
HUP0304058A2 (hu) * 2001-01-30 2004-04-28 Bristol-Myers Squibb Company Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009506988A (ja) * 2005-08-19 2009-02-19 エラン ファーマシューティカルズ，インコーポレイテッド ガンマセクレターゼの架橋ｎ−環状スルホンアミド阻害剤
JP2017523990A (ja) * 2014-08-27 2017-08-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｎｓ障害を処置するための置換ピラジノ［２，１−ａ］イソキノリン誘導体

Also Published As

Publication number Publication date
EP1423119A1 (en) 2004-06-02
WO2002089806A1 (en) 2002-11-14
BR0210060A (pt) 2004-08-17
EP1423119A4 (en) 2005-04-13
CA2446795A1 (en) 2002-11-14
MXPA03010255A (es) 2005-03-07

Similar Documents

Publication Publication Date Title
KR102449652B1 (ko) Rock의 억제제로서의 스피로-융합 시클릭 우레아
US6544987B2 (en) Compounds, compositions, and methods for stimulating neuronal growth and elongation
JP2022503942A (ja) イソインドリン化合物、その調製方法、医薬組成物および使用
JP5643818B2 (ja) Ｋａｔｉｉ阻害剤としての二環式および三環式化合物
WO2019014308A1 (en) 5-CHAIN AND BICYCLIC HETEROCYCLIC AMIDES AS ROCK INHIBITORS
CA2881566A1 (en) 1-(cycloalkyl-carbonyl)proline derivative
KR20190005838A (ko) 이중 lsd1/hdac 억제제로서 사이클로프로필-아마이드 화합물
AU2004251830A1 (en) Pyrido[2, 1-A]-isoquinoline derivatives as DPP-IV inhibitors
EP3828174A1 (en) Pyridazinone derivative
JP5538421B2 (ja) Ｈ３モジュレーターとして使用される置換されたピペリジンスピロピロリジノン及びピペリジノン
KR102842676B1 (ko) Khk 억제 효과를 갖는 화합물
AU2018326497A1 (en) Spirocycle compounds and methods of making and using same
EP2961746A1 (en) Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
JP5139307B2 (ja) ナトリウムチャネルモジュレーターとしてのプロリンアミド誘導体
KR20180016485A (ko) 무스카린성 m2 수용체의 양성 알로스테릭 조정제
KR101857931B1 (ko) 아제티디닐옥시페닐피롤리딘 화합물
AU2008284746A1 (en) Aminopyrazole amide derivative
PT2178858E (pt) Novos compostos heterocíclicos como antagonistas de mglu5
JP5139306B2 (ja) 電位依存性ナトリウムチャネルの調節因子としての第四級α−アミノカルボキサミド誘導体
KR20230035437A (ko) 7-치환된 1-아릴-나프티리딘-3-카르복실산 아미드 및 그의 용도
JP2004532854A (ja) 複素２環式ｆｋｂｐリガンド
EA009059B1 (ru) Замещенные производные азабициклогексана в качестве антагонистов мускаринового рецептора
JP2022545314A (ja) プログラニュリンモジュレーターおよびその使用方法
TW201639836A (zh) 二氮雜－苯並熒蒽類化合物
FR2814167A1 (fr) Preparation de la camptothecine et de ses derives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050509

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20071228